1. Patentable and Non Patentable Biotech Inventions
A Presentation By
D. Calab Gabriel
Senior Partner
K & S Partners, Gurgaon

2. Scope Patent Law What is non patentable Product patent
Case studies –Product Patent
Process Patent
Case studies- Process Patent

3. Patent law Patents Act 1970 Patentable inventions
any product or process which is :
novel
not obvious to a person skilled in the art
capable of industrial application

4. WHAT IS NOT PATENTABLE? (section 3)
(d) New use of known substance/process
Polymorphs, esters, salts, combinations, derivatives that do not show enhanced therapeutic efficacy over known main substance
(e) Mere admixtures (as opposed in synergistic mixtures) and processes thereof
Method of treatment of human beings/animals
(j) Plants, animals parts thereof

5. WHAT IS NOT PATENTABLE? (section 3)
Section 3(d)
3(d) The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant.

6. WHAT IS NOT PATENTABLE? (section 3)
Section 3(d) (cont.)
Explanation: For the purpose of this clause, salts, esters, ethers, polymorphs, metabolites, pure from, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy.
Examples:
Toxic – non-toxic
Stable – shelf life

7. WHAT IS NOT PATENTABLE? (section 3)
(e) a substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof

8. WHAT IS NOT PATENTABLE? (section 3)
(i) any process for the medicinal / surgical / curative, prophylactic/diagnostic/therapeutic or other treatment of human beings or similar such process for treatment in animals.
IN VITRO methods?

9. WHAT IS NOT PATENTABLE? (section 3)
(j) Plants and animals in whole or in part thereof other than microorganisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals.
Cell per se?

10. SECOND MEDICAL USE Section 3(d) New Use of a Known substance
Section 3(e) Mere admixture
Section 3(i) Method of Treatment

11. A FEW OF ACCEPTED CASES INSPITE OF 3(d) OBJECTION
S. no
Application Nos.
Section 3(d): Allowed different “Efficacy “subject matter. 1
2807/DELNP/2004
(Salt)
Far better physiochemical properties i.e. Solubility, non hygroscopicity, distribution coefficient, formulation processability and photo-stability. 2
0844/DELNP/2005
Better physiochemical Properties i.e. better photostability. 3
1046/CAL/1995
(Polymorph,new form)
Better thermal Stability 4
INPCT/2002/00845
(hydrate)
Better stability of heptahydrate over hydrate form 5
0457/KOLNP/2005
(Derivative)
Enhanced Efficacy in Various test procedures and bioassays 6
0609/KOLNP/2003
Lesser Toxicity and better therapeutic Index 7
0482/KOLNP/2005
(Polymorph)
More crystalline form to impart better thermodynamic stability, and purity

12. A FEW OF ACCEPTED CASES INSPITE OF 3(d) OBJECTION - contd
S. No
Application Nos.
Section 3(d): Allowed different “Efficacy “subject matter. 8
1342/KOLNP/2005
(Derivative)
Improved oral Bioavailability 9
1180/MUMNP/2003
(Complex)
Better stability, easily isolated and processed with minimal degradation. 10
656/DELNP/2005
(Polymorph, new forms α- and β- Form)
Form having better Stability under High temperature and relative humidity conditions 11
4719/DELNP/2005
Forms having better Stability under High temperature and relative humidity conditions 12
30/DELNP/2003
Higher magnitude of biological activity against various cancer cells 13
842/DELNP/2005
(Polymorph)
Higher stability (in terms of oral delivery) 14
1599/DELNP/2005
Higher pharmacotherapeutics properties like higher potency and significantly reduced brain access.

13. GLIVEC Test of 3(d) and the product patent regime.
Novartis AG filed patent application No. 1602/MAS/98 on July 17, 1998 for “crystal modification of A N-Phenyl-2-Pyrimidineamine derivative, processes for its manufacture and its use”
Specifically beta form of N-{5-[4-(4-Methyl-piperazino-methyl)-benzoylamido]-2-methyl-phenyl}-4-(3-p yridyl)-2-pyrimidine-amine salt.
( β form of methanesulfonic acid addition salt of a pyrimidine compound and XRD pattern of β form was provided)

14. GLIVEC
X-RD of Beta Form

15. GLIVEC
Notable statement in specification “It goes without saying that all the indicated inhibitory and pharmacological effects of β form are also found with the free base”.
No enhanced efficacy shown
Established β form was pre-existing
Application was rejected by the Patent Office
Limited appeal to DB Chennai, case rejected
Limited issue before IPAB-case rejected
Challenged IPAB decision by way of write in SC

16. TYPICAL BIOTECH INVENTION
Genomic DNA (plant)
Vector
Ligate
Recombinant clone in plasmid vector
Patentable
Protein product
Micro-organism, variants

17. PRODUCT PATENTS
All products of molecular biology: whether for use as drug or food product
Novel micro-organism (isolated/genetically engineered)
Novel gene and peptide sequences
Promoter, Marker
Novel cassette, construct
Vaccine
New viral strain

18. Micro-organisms Not defined by Act
Possibly includes yeast, bacteria, recombinants, DNA sequences, vectors
Are isolated microbes and colonies “mere discovery” ??
Isolates, if characterized, deposited in ID and utility found - patentable
Genetically modified organisms: patentable
Source and origin of Biological material to be provided in specification

19. Genes Gene sequences if isolated and utility found, patentable
Are they ‘part of animal or human being’ ?
Antibodies, including chimeric antibodies are patentable

20. Nucleotide sequences Nucleic Acids: DNA is transcribed into RNA
molecules containing A, G, C and T residues (DNA);
molecules containing A, G, C and U residues (RNA)
DNA is transcribed into RNA
RNA is translated into Proteins
Proteins are molecules containing up to 20 different amino acid residues: A (ala), C (cys), D (asp), E (glu), F (phe), G (gly), H (his), I (ile), K (lys), L (leu), M (met), N (asn), P (pro), Q (gln), R (arg), S (ser), T (thr), V (val), W (trp)
3 nucleic acid residues code for
one amino acid residue:

21. Isolated DNA: EP Position
What is a DNA sequence ? Can it be patented?
Held in RELAXIN CASE : Isolated DNA sequence is a chemical compound; can be patented

22. Isolated DNA: US Position
patentable
An isolated and purified DNA molecule, RNA molecule, or amino acid molecule
isolated chemical compounds
Full-Length Genetic Sequences patentable
Corresponding amino acid sequence patentable

23. ESTs US position- Contd
Partial nucleic acid sequences if proved useful (eg: as encoding protein responsible for diagnosis of a specific disease) = patentable
DNA fragment encoding a full ORF
May be useful if homology to existing nucleic acids or proteins (with an established utility) is at least 95%

24. BOTTOM-LINE Isolated from natural surrounding Utility proven
Nucleotide sequences
The sequence must be isolated and purified from its natural environment
raw sequences with no known use are not patentable
India:
Product patent regime just introduced;
So far few patents granted for nucleotide sequences
Sequences patentable provided:
Isolated from natural surrounding
Utility proven

25. Nucleotide sequences BOTTOM-LINE Claim :
TTT ATT TGT CCT ATT TAA CCT CGT GCT CAT GCT
phe ile cys pro ile stp pro arg ala his ala
Claim :
1.An isolated nucleic acid sequence bearing SEQ ID 1

26. Micro-organisms : EP position
EP case T396/93:
Micro-organism includes bacteria, yeast, fungi, algae, protozoa, virus….
Biotechnology Directive :
Defines biological material not micro-organism
Includes microbes, cell lines, viruses….
Excludes cell lines used for modifying germ line of human beings

27. Micro-organisms : US position
Diamond v. Chakrabarty, 447 U.S. 303 (1980)
genetically engineered bacteria are patentable
“anything under the sun that is made by man”
Patents granted for :
Yeast lines,
Virus, hybridoma, oyester
Harvard Mouse

28. Micro-organisms : Indian position
Section 3:
Plants, animals and human beings except micro-organism not patentable
No distinction between isolated and genetically modified micro-organism
Many argue: Isolated micro-organism is no invention, only GM

29. ISOLATED MICROORGANISM
Mutant ?
Genetically modified ?
Deposit in international depository prior to date of Indian filing

30. LIFE SCIENCES Micro-organism
Also describe source and origin of biological material
Bring out utility
If mutated: set out conditions, details

31. CHARECTERISATION OF YEAST STRAIN
Ex: Mere mention of deposit of yeast strain in a depository without setting out its characteristics in the specification is “inadequate description”
Pfizer’s Application 1974 RPC 689

32. LIFE SCIENCES DNA/Protein Sequences If mutated, how?
Describe fully how sequence was derived
If mutated, how?
Utility/applications of sequence
Products comprising sequence
Sequence listing to be submitted

33. USE OF NEW SUBSTANCE A novel compound X useful for treatment of cancer
Use of compound X for treating cancer
A novel compound X to prepare a medicament Y for treating cancer
Use of compound X to manufacture medicament Y for management of cancer

34. BIO-PRODUCTS Indicate the class and specific chemicals used
Ex: All the oxidants that would enable the invention, all alkali/acids that would help to work the invention

35. EXAMPLE

36. US PATENT NO. 6,764,824
What is claimed is: 1. The primers of SEQ ID NO: 1 and 2 useful for screening human beings for a pre-disposition to schizophrenia.
2. A method of screening human beings for a pre-disposition to schizophrenia by identifying non-sense mutation of codon TGG coding for amino acid tryptophan substituted with TAG, a non-sense codon, at nucleotide No. 825 from 5' end in exon 2 and its allelic variants in synaptogyrin 1 gene of chromosome 22q11-13, said method comprising: (a) isolating DNA from blood leukocytes, (b) amplifying isolated DNA by PCR using primers of SEQ ID NO: 1 and/or 2 of enclosed sequence listing, specific for exons of synaptogyrin 1 gene, (c) sequencing the amplified DNA, (d) comparing the sequenced DNA with that of normal synaptogyrin 1 gene, (e) identifying the said mutation, (f) designing oligonucleotide primer and/or probe of SEQ ID NO: 3 of enclosed sequence listing with its 3' end extending up to penultimate position of said mutation, (g) screening for said non-sense mutation using primer and/or probe of step (f), and (h) screening of said allelic variation for said non-sense mutation using appropriate allele specific oligonucleotide probes and/or primers selected from the group consisting of SEQ ID NO: 4 to 7 of enclosed sequence listing.

37. US PATENT NO. 6,958,224 A chimeric protein αBNAC, of SEQ ID NO:2.
A chimeric protein as claimed in claim 1, wherein said chimeric protein is consists of a total of 177 amino acids.
A chimeric protein as claimed in claim 1, wherein the net charge of each unit of said chimeric protein is -5.
A chimeric protein as claimed in claim 1, wherein said chimeric protein forms beta-sheet structure.
A chimeric protein as claimed in claim 1, wherein the N-terminal domain of said chimeric protein contains nine proline residues.

38. US PATENT NO. 6,616,950
What is claimed is: 1. A fermented fruit based herbal health drink composition useful as an antioxidant, cardio-tonic, diuretic, digestive, choleretic, nervine relaxant and immuno-modulant, comprising extract from plant Andrographis with concentration ranging between 0.5 to 10% in the total herbal health drink, extract from fruit, and ethanol ranging between 3 to 13% in the total herbal health drink, optionally extract from plant Tinospora and other additives.

39. US PATENT NO. 6,558,940
A biologically pure culture of Streptomyces sp. CIMAP A.sub.1 strain bearing ATCC Accession No. PTA-4131 and capable of inhibiting the growth of phytopathogenic fungi.

40. US PATENT NO. 6,696,284
1. A biological filter for the purification of waste gases, comprising a housing with at least one inlet and at least one outlet, and a bed of active micro-organisms contained in a carrier material consisting of pith extracted from coconut husks, the carrier material being provided in the housing such that the waste gases flowing in through the at least one inlet contact the bed of carrier material before exiting through the at least one outlet.

41. US PATENT NO. 6,548,746
1. A new and distinct high alkaloid producing Catharanthus roseus plant called `Dhawal` having NCIMB accession number 41147, and having the following combination of characteristics: (a) plant height of cm, (b) light green to grayish green (emerald green 758/1 color designation from the "Horticultural Colour Chart II") pubescent leaves with distinctly undulating leaf margin, (c) green stem, (d) white flowers, (e) field resistance to die back disease, (f) high leaf yield of 1352 to 2557 kg/ha, (g) 0.89 to 1.40% of total alkaloids in leaves, (h) 1.60 to 2.22% of total alkaloids in roots, (i) a randomly amplified polymorphic DNA (RAPD) profile distinct from the variety `Nirmal` when the DNA is polymerase chain reaction (PCR) amplified by four primers selected from the group consisting of: OPT 06, 09, 16 and 17, and (j) higher herbage and alkaloid yield as compared to the variety `Nirmal`.

42. PROCESS PATENTS Any in vitro process
Method of protein purification, downstream processing
Process using micro-organisms to obtain chemicals

43. Screening Assays Usually patentable Diagnostic assays: grey area
Is it ex-vivo or in-vivo?
Does the result of the method indicate that subject is suffering from a disorder?
If yes, not patentable

44. Examples: PATENTABLE PROCESS
PCR process
Process using microbe …
Novel fermentation products,
novel techniques
- RFLP, AFLP, fingerprinting etc

45. US PATENT
Nano sized sulfide compounds of cerium and a process for the preparation thereof
A bioprocess for the preparation of a sulfide compound of cerium, which comprises the steps of:
a) treating trivalent Cerium salt, optionally in combination with % w/v, of sodium sulfate, with a culture broth of sulfate-reducing bacteria (SRB), containing % v/v, of chloroform, under an inert atmosphere, at a temperature ranging between 25-40° C., at pH of 2 to 6 for a period in the range of 3 to 45 days in single or several installments such that a concentration of trivalent Cerium ions does not exceed 0.1% w/v at any point of time, to obtain a biomass,
b) concentrating the biomass as obtained in step a) at a temperature ranging between 60 to 150° C. for a period in the range of 1 to 6 hours to obtain a concentrated biomass, and
c) treating the concentrated biomass as obtained in step b) at a temperature between 600 to 1500° C. for a period in the range of 5 to 400 minutes followed by separation to obtain a sulfide of Cerium.

46. Chromium free process for the tanning of hides
US PATENT
Chromium free process for the tanning of hides
A chromium free process for the tanning of animal hides which includes, after the standard pretreatment of the hide, covalently modifying the skin collagen of said hide by a process ………..

47. PROCESS FOR THE PREPARATION OF ALKALINE PROTEASE
U.S. PATENT
PROCESS FOR THE PREPARATION OF ALKALINE PROTEASE
A process for the preparation of alkaline protease which comprises growing a fungal strain Conidiobolus coronatus isolated from Anekal, Karnataka, India and deposited in American Type Cell Culture (ATCC) depository under Accession Number PTA-4132, in a medium having pH 6.0 to 9.0, a carbon source and a nitrogen source under aerobic conditions in submerged culture, at a temperature ranging between 20 to 30 C., for a period ranging between 2 to 6 days, harvesting the medium and separating the enzyme in liquid phase.

48. Australian Patent Application no: 2003217445
A method for unhairing animal skins or hides using a total lime and sulfide free enzymatic solution comprising:
preparing an enzymatic solution from animal or plant tissue,
optionally presoaking of skins or hides in water at 10°C to 60°C for 2 to 6 hours,
removing the soaking liquor,
applying the enzymatic solution by pasting or spraying on the flesh side of the skin or hide and left for hours at a temperature ranging between 10°C to 60°C, wherein the skins or hides are arranged flesh side to the flesh side or grain side to grain side,
floating the skins or hides in liquid comprising the enzymatic solution, vi. removing
the skins or hides from the liquid comprising enzymatic solution to produce an effluent and,
unhairing of the skins or hides either by scraping the hair with a curved knife on a wooden beam or by an using unhairing machine.

49. Method for regeneration of organs
A method for regenerating organs in humans using:
stem cells
from contiguous embryonic peritoneal layer
formation of mesodermal organs in vitro
avoids use of exogenous tissue
5 organs regenerated

50. Method for regenerating organs
Patent Act, 1970
sec 3(i) “any process for the medical, surgical, …. treatment of human beings or …render them free of disease ……”
invention in question hit by above provision
currently not patentable in India
US 6,227,202 obtained

51. Method for regeneration of organs

52. Ureter regenerated

53. ?